Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies

https://doi.org/10.1016/j.joca.2014.10.005Get rights and content
Under an Elsevier user license
open archive

Summary

Background

Reports of serious joint adverse events (AEs) due to osteonecrosis were noted during randomized placebo-controlled clinical trials of monoclonal antibodies to nerve growth factor (NGF), including tanezumab and fulranumab.

Methods

All available medical records from subjects with reported cases of osteonecrosis, as well as records of subjects who underwent joint replacement during these studies, were reviewed by an independent adjudication committee that was established by each company; the committees were different for each company and included distinct individual experts. Cases were categorized as having definite osteonecrosis, normal or rapid progression of osteoarthritis (OA), another diagnosis or unable to determine the underlying diagnosis.

Results

The vast majority of investigator reported cases of osteonecrosis were adjudicated as either normal or rapid progression of OA. Indeed, the syndrome of rapid progression of OA associated with chondrolysis and bone destruction appears to be a safety signal that is associated with not only increasing doses of anti-NGF antibodies but also concomitant therapy with nonsteroidal anti-inflammatory drugs.

Conclusions

These results have implications for future clinical trials of anti-NGF agents in OA and other painful conditions.

Keywords

Monoclonal antibodies to nerve growth factor
Tanezumab
Fulranumab
Osteonecrosis
Rapidly progressive osteoarthritis

Cited by (0)

a

Dr Hochberg was a member of the Adjudication Committee for Pfizer Inc., and received compensation for this activity as well as for consulting for Pfizer Inc.